Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Would you consider lenvatinib plus everolimus as first line treatment for a patient with tuberous sclerosis and metastatic renal cell carcinoma?
Related Questions
What factors do you use when selecting which NGS platform to use for sequencing solid tumors?
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
Why are patients getting enzalutamide s/p prostatectomy not candidates for salvage radiation therapy?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
In what situations would a standard FDG PET/CT be useful in the evaluation of high risk prostate cancer?
Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?
What is your preferred subsequent treatment in patients with metastatic bladder cancer with progression on pembrolizumab/enfortumab?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
